A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy

Trial Profile

A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2018

At a glance

  • Drugs Golimumab (Primary) ; Methotrexate
  • Indications Juvenile rheumatoid arthritis
  • Focus Pharmacokinetics; Registrational
  • Acronyms GO-VIVA
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 06 Aug 2018 Planned primary completion date changed from 28 Jun 2018 to 21 Feb 2023.
    • 22 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 24 Mar 2017 Planned End Date changed from 1 Oct 2022 to 21 Feb 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top